SUMMARY
Abstract
Despite a $64 billion global aesthetic market, only 10% of potential aesthetic patients are currently receiving treatments. This leaves 90% of the market untapped, often due to concerns about cost, invasiveness, recovery time, and fear of surgery. This paper investigates this “treatment gap” and presents a solution through InMode’s minimally and non-invasive technologies—such as Morpheus8, Evoke, and Evolve—that cater to this hesitant majority by offering clinically proven results with reduced downtime.
Conclusion
The study concludes that bridging the treatment gap is a major growth opportunity in the aesthetic space. InMode’s technologies—especially Morpheus8, Evoke, and Evolve—effectively meet the demand for safe, efficient, and low-downtime solutions. Providers who adopt these tools can expand their patient base, improve accessibility, and achieve significant revenue growth while delivering natural, reproducible outcomes.
TOPICS COVERED
- Definition and quantification of the aesthetic treatment gap
- Analysis of patient behavior: 90% of aesthetic-interested consumers are not being treated
- Key deterrents: fear of surgery, cost, social downtime, and unnatural results
- InMode’s non-invasive solutions: Morpheus8, Evoke, and Evolve Transform/Tone
- Shifting market trends toward non-surgical facial and body rejuvenation
- Revenue growth potential for practices adopting RF-based technologies
- Strategies for engaging the hesitant patient population
